Potential of pharmacokinetic profiling for detecting herbal interactions with drugs

Clinical Pharmacokinetics

Volumn 47, Issue 6, 2008, Pages 383-397

  Butterweck, Veronika ^a   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Cytochrome P450; Drug interactions; Herbal medicines, drug interactions; Herbal medicines, pharmacokinetics; Pharmacokinetic modelling

Indexed keywords

ALLYL SULFIDE; CAFFEINE; CHLORZOXAZONE; CHRYSIN; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A1; CYTOCHROME P450 3A4; DIALLYL DISULFIDE; DIALLYL TRISULFIDE; FLUVOXAMINE; GARLIC EXTRACT; GLYCOPROTEIN P; HERBACEOUS AGENT; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; MIDAZOLAM; QUERCETIN; S ALLYLCYSTEINE; S METHYLCYSTEINE; UNINDEXED DRUG;

AREA UNDER THE CURVE; COMPUTER MODEL; DRUG BIOAVAILABILITY; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME INDUCTION; ENZYME INHIBITION; HERBAL MEDICINE; HUMAN; IC 50; IN VITRO SELECTION; LIVER METABOLISM; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; SCREENING; SINGLE DRUG DOSE;

ANIMALS; BIOLOGICAL TRANSPORT; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; ENZYME INDUCTION; HERB-DRUG INTERACTIONS; HUMANS; MODELS, ANIMAL; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 43649084621     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200847060-00003     Document Type: Review

References (124)

1. Brevoort P. The US botanical market: an overview. Herbalgram 1996; 36: 49-57
2. Brevoort P. The booming US botanical market: a new overview. Herbalgram 1998; 44: 33-46
3. Kessler RC, Davis RB, Foster DF, et al. Long-term trends in the use of complemen- tary and alternative medical therapies in the United States. Ann Intern Med 2001; 135: 262-8
4. Strandell J, Neil A, Carlin G. An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 2004; 11 (2-3): 98-104
5. Blumenthal M. Herbs and phytomedicines in the European Community. In: Blumenthal M, editor. The complete German Commission E monographs therapeu-tic guide to herbal medicines. Austin (TX): American Botanical Council, 1998: 17-18
6. Hammerness P, Basch E, Ulbricht C, et al. St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 2003; 44: 271-82
7. Henderson L, Yue QY, Bergquist C, et al. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54 (4): 349-56
8. Schulz V. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine 2001; 8 (2): 152-60
9. Butterweck V, Derendorf H, Gaus W, et al. Pharmacokinetic herb-drug interactions: are preventive screenings necessary and appropriate? Planta Med 2004; 70 (9): 784-91
10. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001; 61 (15): 2163-75
11. Boon H, Jurgens T. Drug interactions with natural health products: a discussion paper. Ottawa (ON): Health Canada, 2001 Nov [online]. Available from URL: http://www.hc-sc.gc.ca/dhp-mps/pubs/complement/interaction_drug- medicament_11-01/index_e.html [Accessed 2008 Apr 9]
12. Burchell B, Brierley CH, Monaghan G, et al. The structure and function of the UDP-glucuronosyltransferase gene family. Adv Pharmacol 1998; 42: 335-8
13. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40: 581-616
14. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29 (1-2): 413-580
15. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52 (4): 349-55
16. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4 (6): 285-99
17. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32 (3): 210-58
18. Guengerich FP. Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 1997; 43: 7-35
19. Obach RS, Zhang QY, Dunbar D, et al. Metabolic characterization of the major human small intestinal cytochrome p450s. Drug Metab Dispos 2001; 29 (3): 347-52
20. Zhang QY, Dunbar D, Ostrowska A, et al. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 1999; 27 (7): 804-9
21. Peters WH, Kock L, Nagengast FM, et al. Biotransformation enzymes in human intestine: critical low levels in the colon? Gut 1991; 32 (4): 408-12
22. Bergheim I, Bode C, Parlesak A. Distribution of cytochrome P450 2C, 2E1, 3A4, and 3A5 in human colon mucosa. BMC Clin Pharmacol 2005; 5: 4
23. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998; 280 (18): 1569-75
24. Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002; 72 (3): 276-87
25. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287 (3): 337-44
26. Tindle HA, Davis RB, Phillips RS, et al. Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med 2005; 11 (1): 42-9
27. Lee LS, Andrade AS, Flexner C. Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. Clin Infect Dis 2006; 43 (8): 1052-9
28. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35 (5): 361-90
29. Grimm SW, Bend JR, Halpert JR. Selectivity and kinetics of inactivation of rabbit hepatic cytochromes P450 2B4 and 2B5 by N-aralkylated derivatives of 1-aminobenzotriazole. Drug Metab Dispos 1995; 23 (5): 577-83
30. Halpert JR. Structural basis of selective cytochrome P450 inhibition. Annu Rev Pharmacol Toxicol 1995; 35: 29-53
31. Foster BC, Foster MS, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001; 4 (2): 176-84
32. Teyssier C, Guenot L, Suschetet M, et al. Metabolism of diallyl disulfide by human liver microsomal cytochromes P-450 and flavin-containing monooxygenases. Drug Metab Dispos 1999; 27 (7): 835-41
33. Jin L, Baillie TA. Metabolism of the chemoprotective agent diallyl sulfide to glutathione conjugates in rats. Chem Res Toxicol 1997; 10 (3): 318-27
34. Greenblatt DJ, Leigh-Pemberton RA, von Moltke LL. In vitro interactions of water-soluble garlic components with human cytochromes p450. J Nutr 2006; 136 (3 Suppl.): 806S-9S
35. Lawson LD, Wang ZJ, Hughes BG. Identification and HPLC quantitation of the sulfides and dialk(en)yl thiosulfinates in commercial garlic products. Planta Med 1991; 57 (4): 363-70
36. Gorski JC, Huang SM, Pinto A, et al. The effect of Echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004; 75 (1): 89-100
37. Piscitelli SC, Burstein AH, Welden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34 (2): 234-8
38. Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002; 23 (5): 687-702
39. Kliewer SA, Willson TM. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J Lipid Res 2002; 43 (3): 359-64
40. Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 2001; 98 (6): 3369-74
41. Moore LB, Goodwin B, Jones SA, et al. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000; 97 (13): 7500-2
42. Wentworth JM, Agostini M, Love J, et al. St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000; 166 (3): R11-6
43. Foster BC, Vandenhoek S, Hana J, et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003; 10 (4): 334-42
44. Rengelshausen J, Banfield M, Riedel KD, et al. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 2005; 78 (1): 25-33
45. Wang Z, Hamman MA, Huang SM, et al. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002; 71 (6): 414-20
46. Cantoni L, Rozio M, Mangolini A, et al. Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse. Toxicol Sci 2003; 75 (1): 25-30
47. Butterweck V, Christoffel V, Nahrstedt A, et al. Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models. Life Sci 2003; 73 (5): 627-39
48. Gatmaitan ZC, Arias IM. Structure and function of P-glycoprotein in normal liver and small intestine. Adv Pharmacol 1993; 24: 77-97
49. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248-60
50. Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283 (3): 1552-62
51. Harris RZ, Jang GR, Tsunoda S. Dietary effects on drug metabolism and transport. Clin Pharmacokinet 2003; 42 (13): 1071-88
52. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug antiretroviral tions. Br J Clin Pharmacol 1995; 40 (6): 523-30
53. US Dietary Supplement Health and Education Act of 1994 Pub. L. 103-417
54. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004; 18 (19): 2273-81
55. Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002; 71: 1579-89
56. Bapiro TE, Egnell AC, Hasler JA, et al. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 2001; 29 (1): 30-5
57. Budzinski JW, Foster BC, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7 (4): 273-82
58. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000; 294 (1): 88-95
59. Chang WH, Augustin B, Lane HY, et al. In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. Psychopharmacology 1999; 145: 91-8
60. Li AP, Rasmussen A, Xu L, et al. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. J Pharmacol Exp Ther 1995; 274 (2): 673-7
61. Sidhu JS, Farin FM, Omiecinski CJ. Influence of extracellular matrix overlay on phenobarbital-mediated induction of CYP2B1, 2B2, and 3A1 genes in primary adult rat hepatocyte culture. Arch Biochem Biophys 1993; 301 (1): 103-13
62. Ekins S, Bravi G, Ring BJ, et al. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. J Pharmacol Exp Ther 1999; 288 (1): 21-9
63. Ekins S, de Groot MJ, Jones JP. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. Drug Metab Dispos 2001; 29 (7): 936-44
64. Lee H, Yeom H, Kim YG, et al. Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. Biochem Pharmacol 1998; 55 (9): 1369-75
65. Walle T, Otake Y, Brubaker JA, et al. Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br J Clin Pharmacol 2001; 51 (2): 143-6
66. Zuber R, Modriansky M, Dvorak Z, et al. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res 2002; 16 (7): 632-8
67. Palmer JL, Scott RJ, Gibson A, et al. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). Br J Clin Pharmacol 2001; 52 (5): 555-61
68. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003; 43: 443-69
69. Huang S-M, Hall SD, Watkins P, et al. Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther 2004; 75 (1): 1-12
70. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38 (1): 41-57
71. Bailey DG, Kreeft JH, Munoz C, et al. Grapefruit juice-felodipine interaction: effect of naringin and 6′,7′-dihydroxybergamottin in humans. Clin Pharmacol Ther 1998; 64 (3): 248-56
72. Bailey DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46 (2): 101-10
73. Saito M, Hirata-Koizumi M, Matsumoto M, et al. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf 2005; 28 (8): 677-94
74. Saito M, Hirata-Koizumi M, Miyake S, et al. Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK). Eur J Clin Pharmacol 2005; 61 (7): 531-6
75. Dreier JP, Endres M. Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology 2004; 62 (4): 670
76. Nakahara K, Kuriyama M, Sonoda Y, et al. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol 1998; 152 (1): 99-106
77. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63 (4): 397-402
78. Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 2004; 58 (1): 56-60
79. Rogers JD, Zhao J, Liu L, et al. Grapefruit juice has minimal affects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther 1999; 66 (4): 358-66
80. Fukazawa I, Uchida N, Uchida E, et al. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br J Clin Pharmacol 2004; 57 (4): 448-55
81. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant pattients: are the statins mechanistically similar? Pharmacol Ther 1998; 80 (1): 1-34
82. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004; 76 (5): 428-40
83. Meibohm B, Derendorf H. Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci 2002; 91 (1): 18-31
84. Madabushi R, Frank B, Drewelow B, et al. Hyperforin in St John's wort drug interactions. Eur J Clin Pharmacol 2006; 62 (3): 225-33
85. Mills E, Montori VM, Wu P, et al. Interaction of St John's wort with conventional drugs: systematic review of clinical trials. BMJ 2004; 329 (7456): 27-30
86. Mueller SC, Majcher-Peszynska J, Uehleke B, et al. The extent of induction of CYP3A by St John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 2006; 62 (1): 29-36
87. Mai I, Bauer S, Perloff ES, et al. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004; 76 (4): 330-40
88. Müller WE, Singer A, Wonnemann M. Hyperforin: antidepressant activity by a novel mechanism of action. Pharmacopsychiatry 2001; 34 Suppl. 1: S98-102
89. Müller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract. Pharmacopsychiatry 1998; 31 Suppl. 1: 16-21
90. Kaufeler R, Meier B, Brattstrom A. Efficacy and tolerability of Ze 117 St John's wort extract in comparison with placebo, imipramine and fluoxetine for the treatment of mild to moderate depression according to ICD-10: an overview. Pharmacopsychiatry 2001; 34 Suppl. 1: S49-50
91. Ernst E. Second thoughts about safety of St John's wort. Lancet 1999; 354 (9195): 2014-6
92. Yue QY, Bergquist C, Gerden B. Safety of St John's wort (Hypericum perforatum). Lancet 2000; 355 (9203): 576-7
93. Donath F, Roots I, Langheinrich M, et al. Interactions of St John's wort extract with phenprocoumon [abstract]. Eur J Clin Pharmacol 1999; 55: A22
94. Barone GW, Gurley BJ, Ketel BL, et al. Drug interaction between St John's wort and cyclosporine. Ann Pharmacother 2000; 34: 1013-6
95. Breidenbach T, Hoffmann MW, Becker T, et al. Drug interaction of St John's wort with cyclosporin. Lancet 2000; 355: 1912
96. Mai I, Kruger H, Budde K, et al. Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporine. Int J Clin Pharmacol Ther 2000; 38 (10): 500-2
97. Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355 (9203): 548-9
98. Mai I, Stromer E, Bauer S, et al. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003; 18: 819-22
99. Markowitz JS, DeVane CL. The emerging recognition of herb-drug interactions with a focus on St John's wort (Hypericum perforatum). Psychopharmacol Bull 2001; 35 (1): 53-64
100. Murphy PA, Kern SE, Stanczyk FZ, et al. Interaction of St John's wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 2005; 71 (6): 402-8
101. Nebel A, Schneider BJ, Baker RK, et al. Potential metabolic interaction between St John's wort and theophylline. Ann Pharmacother 1999; 33: 202
102. Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66 (4): 338-45
103. Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John's wort. Lancet 2000; 355 (9203): 547-8
104. de Matt MMR, Hoetelmans RMW, Mathot RAA, et al. Drug interactions between St John's wort and nevirapine. AIDS 2001; 15 (3): 420-1
105. Barbanel DM, Yusufi B, O'Shea D. Mania in patient receiving testosterone replacement post-orchidetomy taking St John's wort and sertraline. J Psychopharmacol 2000; 14: 84-6
106. Lantz MS, Buchalter E, Giambanco V. St John's wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999; 12 (1): 7-10
107. Morazzoni P, Bombardelli E. Silybum marianum (Carduus marianus). Fitoterapia 1995; 66: 3-42
108. Arnone A, Merlini L, Zanarotti A. Constituents of Silybum marianum: structure of isosilybin and stereochemistry of isosilybin. J Chem Soc Chem Commun 1979: 696-7
109. 6), the first flavonolignan. Tetrahedron Lett 1969; 25: 2911-6
110. Wagner H, Seligman O, Seilz M, et al. Silydanin und Silychristin, zwei isomere Silymarine aus Silybum marianum. Z Naturforsch 1976; 31b: 876-84
111. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001; 61 (14): 2035-63
112. DiCenzo R, Shelton M, Jordan K, et al. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 2003; 23 (7): 866-70
113. Piscitelli SC, Formentini E, Burstein AH, et al. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 2002; 22 (5): 551-6
114. Mills E, Wilson K, Clarke M, et al. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur J Clin Pharmacol 2005; 61 (1): 1-7
115. van Erp NP, Baker SD, Zhao M, et al. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 2005; 11 (21): 7800-6
116. Gurley B, Hubbard MA, Williams DK, et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol 2006; 46 (2): 201-13
117. Gurley BJ, Barone GW, Williams DK, et al. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 2006; 34 (1): 69-74
118. Barnes J, Anderson LA, Phillipson JD. Herbal medicines. 2nd ed. Bath: The Bath Press, 2002
119. Koch HP, Reuter HD. Garlic: the science and therapeutic application of Allium sativum L. and related species. Baltimore (MD): Williams and Wilkins, 1996
120. Reuter HD. Allium sativum and Allium ursinum: part 2 - pharmacology and medicinal application. Phytomedicine 1995; 2 (1): 73-91
121. Lawson LD. Garlic: a review of its medicinal effects and indicated active compounds. In: Lawson DL, Bauer R, editors. Phytomedicines of Europe: chemistry and biological activity. Washington, DC: American Chemical Society, 1998: 176-209
122. Wu CC, Sheen LY, Chen HW, et al. Differential effects of garlic oil and its three major organosulfur components on the hepatic detoxification system in rats. J Agric Food Chem 2002; 50 (2): 378-83
123. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 1997; 25 (2): 256-66
124. Gallicano K, Foster B, Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2003; 55 (2): 199-202